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ABSTRAK
Megakaryoblastik leukemia adalah sejenis myeloid leukemia akut yang sering 
dihidapi bayi penghidap sindrom Down. Megakaryoblastik leukemia dengan 
translokasi t(1;22)(p13;q13) adalah sejenis myeloid leukemia akut yang jarang ditemui 
dan meliputi hanya <1% bagi semua kes. Ia dilaporkan berlaku hanya kepada bayi 
penghidap megakaryoblastik leukemia yang tidak mengalami sindrom Down. 
Ia lebih melibatkan bayi perempuan dan translokasi sitogenetik ini dilaporkan 
mempunyai impak yang buruk kepada prognosis pesakit. Kami melaporkan kes 
yang jarang ditemui ini berlaku kepada seorang bayi perempuan berumur 9 bulan 
yang menunjukkan simptom tanda-tanda lebam, pembengkakan hati dan limpa 
yang serius dan pembengkakan kelenjar limfa servikal dan inguinal. Darah periferi 
menunjukkan  anemia yang serius, ovalositosis, trombositopenia dan sel darah putih 
yang tinggi. Sum-sum tulang menunjukkan kepadatan sel-sel blast yang mempunyai 
ratio nukleus-sitoplasmic yang tinggi dan sitoplasm tanpa granul dan blebs. Ujian 
peroksidase adalah negatif. Ujian imunofenotip menunjukkan ekspresi penanda 
CD117, CD 13, CD33 dan CD61 yang mengesahkan diagnosa megakaryoblastik 
leukemia akut. Menariknya, ujian sitogenetik menunjukkan kehadiran translokasi 
t(1;22) yang dilaporkan berlaku kepada bayi yang tidak mengalami sindrom Down 
berlaku pada kes ini. Pesakit ini menerima rawatan rejim kemoterapi mengikut 
protokol AML trial 15 ADE dan sebagai kesannya telah mengalami neutropenik 
sepsis yang serius dan masalah pernafasan yang memerlukan bantuan pernafasan 
dan faktor stimulasi koloni granulosit (G-CSF). Walaubagaimanapun, pesakit 
tidak menghadiri sesi temujanji seterusnya setelah sembuh dan beberapa bulan 
kemudian kembali dengan penyakit myeloid lukemia akut berulang.
Kata kunci: Leukemia infantil,translokasi (1;22), non-Down Syndrome
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ABSTRACT
Megakaryoblastic leukaemia is the commonest form of leukaemia occuring in 
Down syndrome infants. However, it’s subtype with translocation t(1;22)(p13;q13) 
is uncommon comprising <1% of all cases and reported to exclusively occur 
in infant without Down syndrome. It has a female predominance and carries a 
poor prognosis. We described this rare form of leukaemia in a 9-month-old girl 
who presented with bruises, massive hepatosplenomegaly and multiple cervical 
and inguinal lymphadenopathy. The blood film showed severe anaemia with 
ovalostomatocytosis, thrombocytopenia and mild  leucocytosis. The bone marrow 
aspirate showed numerous blasts showing high nuclear-cytoplasmic ratio and 
agranular cytoplasm with cytoplasmic blebs. Peroxidase staining was negative. The 
immunophenotyping of the blasts showed positive expression of CD117, CD13, CD33 
and CD61 which confirmed the diagnosis of acute megakaryoblastic leukaemia. 
Interestingly, the cytogenetic finding of translocation t(1;22) which is most common 
in acute megaloblastic leukaemia in infants without Down syndrome was found in 
this case. She received the AML trial 15 ADE protocol chemotherapy regime and 
developed severe neutropenic sepsis and respiratory distress requiring ventilatory 
support and granulocyte colony stimulating factor (G-CSF). She recovered well 
after the first course of chemotherapy and was discharged. Unfortunately, she 
was not brought in for follow-up chemotherapy and presented a few months later 
with relapsed AML. She was re-started on ADE protocol and currently is on oral 
thioguanine for maintenance therapy.
Keywords: Infantile leukaemia , translocation (1;22), non-Down Syndrome
et al. 1991). It was reported that its 
incidence is highest among infants with 
Down syndrome and is associated with 
mediastinal germ cell tumors (Swerdlow 
et al. 2008). 
 The t(1;22) is an uncommon 
abnormality in AML, constituting less 
than 1% of all AML cases. It is found 
most commonly among non-Down 
syndrome infants, predominantly in 
females. AML with t(1;22) is a de novo 
AML, restricted to infants and young 
children, with most cases occuring in 
the first six months of life. It is associated 
with t(1;22)/RBM15-MKL1 resulting 
in expression of the one twenty-two 
megakaryocytic acute leukaemia (OTT-
INTRODUCTION
AML constitutes 15-20% of all acute 
leukaemia cases in children 15 years 
and below. According to the National 
Cancer Registry of Cancer Incidence 
in Malaysia 2007, the incidence of 
AML is 2.8 per 100,000 population. 
The age specific cancer incidence per 
100,000 population for 0-9 years of age 
in Malaysia is 3-6 for males and 2-4 for 
females.    
 Acute megakaryoblastic leukemia 
(AML M7) is an uncommon subtype 
of AML, occuring in approximately 
10% of paediatric and 5% of adult 
AML (Bernstein et al. 2000, Carroll 
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MAL) fusion gene (Carroll et al. 1991; 
Ma et al. 2001; Mercher et al. 2009). The 
expression of  OTT-MAL fusion gene 
results in abnormal megakaryocyte 
development. The megakaryopoiesis 
changes include enhancement in the 
cells self-renewal ability. Apart from 
that there is activation of recombination 
signal binding protein for imunoglobulin 
J kappa region (RBPJ)-mediated 
transcription (Mercher et al. 2009). It is 
suggested that prenatal genetic factors 
are involved in leukaemogenesis in 
these AML M7 infants having t(1;22) 
(Carroll et al. 1991). These infants usually 
present with huge hepatosplenomegaly, 
anaemia, thrombocytopenia and 
moderate elevation of the white 
blood cell count. At presentation, they 
commonly come with cytopenias, 
particularly thrombocytopenia, 
however some may have normal or 
increased in platelet count.
 The megakaryoblasts show 
similar morphological features in all 
AML-M7 with or without t(1;22). The 
blasts are heterogenous with some 
undifferentiated blast cells resembling 
lymphoblasts. These megakaryoblasts 
are medium to large in size with slight 
irregular or indented nucleus with fine 
reticular chromatin and prominent 
nucleoli. They have basophilic 
cytoplasm, often agranular and some 
showed distinct blebs or pseudopod 
formation (Swerdlow et al. 2008). 
The bone marrow biopsy may show 
hypercellular marrow with evidence 
of fibrosis (Carroll et al. 1991). These 
marrow fibrosis may be attributable to 
the secretion of fibrogenic cytokines 
by the megakaryoblasts (Carroll et al. 
1991).
 Immunophenotypically, the 
megakaryoblasts express one or more 
platelet glycoprotein CD41 (glycoprotein 
IIb/IIIa), and/or CD61 (glycoprotein 
IIIa) and other myeloid markers CD13 
and CD33. The more mature platelet-
associated marker CD42 (glycoprotein 
Ib) is less frequently expressed. CD34, 
CD45, MPO and HLA-DR are usually 
negative (Swerdlow et al. 2008). 
 Therapy of AML generally consists 
of aggressive multi-drug chemotherapy 
regimens consisting of cytarabine, 
anthracyclines (daunorubicin, 
idarubicin, and mitoxantrone) and 
etoposide (Bain 2007) aimed to 
eliminate the leukaemic cells and 
achieve a complete haematological 
remission (CR). Our centre used the 
AML 15 protocol similar to a study trial 
conducted in Birmingham. 
 AML M7 has a better prognosis 
among Down’s syndrome infants, 
with a four year event free survival of 
73%. The prognosis in both children 
and adults with AML M7 with t(1;22) is 
poor, primarily attributable to a resistant 
disease (Bain, 2007). Approximately 
50% of patients will obtain an initial 
remission with cytarabine and 
anthracycline but with only 10.5 
months median survival (Carroll et al. 
1991). Bone marrow transplantation is 
indicated in all cases of AML M7 with 
t(1;22) (Lion et al. 1992). However, 
long term survivors following intensive 
therapies have been reported (Reinhardt 
et al. 2005).  
 CASE REPORT
A 9-month-old baby girl presented 
to our centre with pallor, lethargy, 
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abdominal distension, loose stool, 
vomiting and reduced oral intake 
of two weeks duration. On physical 
examination, she was noted to be 
underweight with failure to thrive, pale 
and tachypnoeic. There were huge 
hepatosplenomegaly and  multiple 
lymphadenopathies involving the 
cervical, axillary, inguinal, and occipital 
region. Areas of ecchymoses were 
noted on her back. A soft systolic 
murmur was present with displaced 
apex beat at the 6th intercostal space, 
1 cm lateral to the mid-clavicular line.
 Full blood count showed severe 
anaemia with haemoglobin of 2.6 g/
dL, leukocyte count of 19.9 x 109/L, 
and platelet count of 23 x 109/L. The full 
blood picture revealed severe anaemia, 
ovalostomatocytosis, thrombocytopenia 
with leukoerythroblastic picture and 
presence of blasts (Figure 1, 2). The 
bone marrow aspirate showed presence 
of 60% blasts which are heterogenous 
in size. The blasts have high nucleo-
cytoplasmic ratio, immature nuclei, 
inconspicuous nucleoli, and abundant 
basophilic cytoplasm. Some of the 
blasts have cytoplasmic blebs. No Auer 
rods or granules are noted within the 
cytoplasm (Figure 3). The peroxidase 
stain was negative (Figure 4). 
 Immunophenotyping of the 
bone marrow aspirate performed 
Figure 1: Full blood picture showing 
severe anaemia with ovalostomatocytes.         
(Wright’s stain x40)
Figure 2: Presence of blast cell in the 
full blood picture. The blast show 
cytoplasmic blebs. (Wright’s stain x40)
Figure 3: Blasts with cytoplasmic blebs.   
(MGG stain x40)
Figure 4: The megakaryoblasts are 
negative to Myeloperoxidase stain.                      
(Peroxidase stain, x40)
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demonstrated an abnormal population 
of blasts expressing CD117, CD13, 
CD33(dim) and CD61 and negative for 
other B and T cell markers consistent 
with acute megakaryoblastic leukaemia. 
The trephine biopsy was inconclusive 
as the sample was unsatisfactory. 
Interestingly, the cytogenetic study 
showed translocation between 
chromosome 1 and chromosome 22 
(t(1;22)(p13;q13)) in sixteen metaphase 
spreads (Figure 5). Flourescent in situ 
hybridisation (FISH) analysis showed 
no visible BCR/ABL, TEL/AML1, or MLL 
gene rearrangement. The serum lactate 
dehydrogenase (LDH) was markedly 
elevated (7916 U/L). 
 She received multiple transfusion 
of packed cells, platelets and was 
started on the ADE chemotherapy 
protocol which consist of cytosine 
arabinoside (Ara-C), daunorubicin and 
etoposide. She developed haematuria 
following platelet transfusion which 
after ultrasound of the kidney revealed 
mild to moderate hydronephrosis with 
hydroureter. 
 During the course of chemotherapy, 
she developed neutropenic sepsis with 
bronchopneumonia complicated with 
acute respiratory distress and needed 
intensive care monitoring, continuous 
positive airway pressure (CPAP) and 
inotrope support. She was ventilated 
for 12 days and was given broad 
spectrum antibiotics Meropenem 
and Amphocil, as well as granulocyte 
colony-stimulating factor (G-CSF) to 
increase the neutrophil counts. Her 
condition improved and was allowed 
for discharge after one week recovery. 
The parents were informed to bring her 
for follow up within a week for further 
management. Unfortunately, her 
parents defaulted the follow-up. A few 
months later the child was brought in 
with relapsed acute myeloid leukaemia. 
She was re-started on the ADE protocol 
Figure 5: High resolution karyotyping result showing the t(1;22)(p13;q13).
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and completed the cycles. Currently 
she is well and is on maintenance 
chemotherapy with oral thioguanine 
and sub-cutaneous Ara-C.
DISCUSSION 
Acute megakaryoblastic leukaemia 
(AML M7) is an uncommon subtype of 
AML, comprising approximately 10% 
of paediatric and 5% of adult AML 
(Bernstein et al. 2000; Carroll et al. 
1991). It has a bimodal age distribution 
that peaks in early childhood, normally 
in children less than 3 years of age and 
adulthood (Gewirtz et al. 1989; Ribeiro 
et al. 1993). In a large series of childhood 
AML from a single institution, 14.6% of 
all cases of AML were identified as AML 
M7 (Athale et al. 2001). The incidence 
of AML M7 is much higher than what 
was previously reported. This could 
be attributed to the complexity of its 
clinical presentation and difficulty in 
obtaining and interpretating the bone 
marrow samples for diagnostic testing 
(Ravindranath et al. 1992). Thus, many 
of these AML M7 cases may have 
been diagnosed as undifferentiated 
leukaemia, myelodysplastic syndrome, 
myelofibrosis or other disease (Athale 
et al. 2001). Currently, the improvement 
in knowledge on the morphology, 
cytochemistry, and immunophenotyping 
of the megakaryoblasts, together with 
the advancement in cytogenetic testing 
have allowed a more accurate and 
reliable diagnosis of AML M7 as well 
as determination of the character and 
prognosis of this disease. 
 In children, the incidence of AML 
M7 is highest among infants with 
Down syndrome with trisomy 21 and 
also in children with mediastinal germ 
cell tumors (Swerdlow et al. 2008). 
 In contrast, AML M7 in infants 
without Down syndrome is found to 
be exclusively associated with t(1;22)/
RBM15-MKL1 resulting in fusion of 
the OTT(RBM15) gene on 1p13 to the 
MAL(MLK1) gene on chromosome 
22, leading to the OTT-MAL fusion 
gene on the derivative 22 (Swerdlow 
et al. 2008; Carroll et al. 1991; Ma 
et al. 2001; Mercher et al. 2009). It 
is an uncommon subtype in AML, 
constituting less than 1% of all AML 
cases and found most commonly 
among non-Down syndrome infants, 
predominantly in females. Other 
cytogenetic abnormalities that may be 
present in these non-Down syndrome 
infants with acute megakaryoblastic 
leukaemia includes inv(3)(q21;q26), 
which is not specific to AML-M7 and 
may be seen in other types of AML 
(Edmond et al. 2001). The insertion(12p) 
can also be found among patients with 
AML-M7 but it is more commonly 
associated with mediastinal germ cell 
tumours (Edmond et al. 2001). 
 AML with t(1;22) is a de novo AML, 
restricted to infants and young children, 
with most cases occuring in the first 
six months of life. It is suggested that 
prenatal genetic factors are involved 
in leukaemogenesis in these AML M7 
infants with t(1;22) (Carroll et al. 1991). 
These infants usually present with 
huge hepatosplenomegaly, anaemia, 
thrombocytopenia and moderate 
leucocytosis. Cytopenias, particularly 
thrombocytopenia, are common at 
presentation but the platelet count can 
be normal or even increased in some 
cases. Characteristically, there is no 
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preceeding myelodysplasia, or history 
of transient leukaemoid reaction in 
these infants (Verschuur et al. 2004). 
These features were well illustrated  as 
reported in our case.   
 The morphological features of the 
blasts presented in our patient were 
similar to that described for AML M7 
with or without t(1;22). In addition, 
the stromal pattern of bone marrow 
infiltration by these megakaryoblasts 
may mimic a metastatic tumour. The 
blasts are usually myeloperoxidase 
negative, but are positive for acid 
phosphatase and alpha-naphthyl 
acetate esterase (sodium fluoride 
resistant). 
 Immunophenotypically, the 
megakaryoblasts express platelet 
glycoproteins, namely CD41 
(glycoprotein IIb/IIIa), and/or CD61 
(glycoprotein IIIa), together with the 
myeloid markers of CD13 and CD33. 
CD34, CD45, MPO and HLA-DR are 
usually negative (Swerdlow et. al 2008). 
The immunophenotyping from our 
patient showed expression of  CD117, 
CD13, CD61 and CD33(dim) which are 
consistent with the diagnosis of AML M7. 
  Based on the general principle of 
leukaemia therapy, there are multiple 
chemotherapy protocols available from 
different centres conducting these trial 
studies. Among them is the AML 15 
trial study conducted in Birmingham 
in which our patient’s treatments 
were based upon. The ADE 10+3+5 
protocol from the AML 15 trial were 
used. Each course of chemotherapy 
results in a temporary bone marrow 
suppression, leading to prolonged 
anaemia,  leukopenia, neutopenia and 
thrombocytopenia. The prolonged 
myelosuppression often render the 
patients susceptible to opportunistic 
bacterial, fungal or viral infection, which 
can be life-threatening. Moreover, the 
chemotherapy courses can also cause 
varying degree of mucositis, which is 
caused by the cytotoxic effect of the 
chemotherapy agents on the epithelium 
of the intestinal tract, thus requiring 
various supportive measures.  
 The prognosis in both children and 
adults with this form of leukemia is 
poor, primarily attributing to its resistant 
disease (Bain‘ 2007).  Approximately 
50% of patients will obtain an initial 
remission with cytarabine and 
anthracycline but the median survival is 
only 10.5 months (Carroll et al. 1991). 
AML M7 has a better prognosis among 
Down’s syndrome infants, with a 4 year 
event free survival of 73% and bone 
marrow transplantation is indicated in 
cases of AML M7 with t(1;22) (Lion et 
al. 1992). However, long term survivors 
following intensive therapies have been 
reported (Reinhardt et al. 2005).  
 In conclusion, AML M7 is a 
heterogenous disease affecting the 
two extreme ages and carries a poor 
prognosis, contributed by the resistant 
nature of the disease. AML M7 
commonly affect infants with  Down’s 
syndrome or associated with t(1;22) 
in those with non-Down syndrome. 
Early recognition and diagnosis of AML 
M7 especially to identify the subtype 
with t(1;22) is very crucial to stratify 
these patients to the more intensive 
management in order to achieve good 
response to treatment and improving 
their overall survival.  We highlighted 
a case of an infant with a rare subtype 
of AML M7 with t(1;22) who had 
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successfully undergone an intensive 
series of chemotherapy and currently 
well on maintenance treatment.
REFERRENCES
Athale, U.H., Razzouk, B.I., Raimondi, S.C., Tong, 
X., Behm, F.G., Head, D.R., Srivastava, D.K., 
Rubnitz, J.E., Bowman, L., Pui, C.H. & Ribeiro, 
R.C. 2001. Biology and outcome of childhood 
acute megakaryoblastic leukaemia: a single 
institution experience. Blood 97(12): 3727-3732.
Bain, B.J. 2007. Diagnosis and classification of acute 
leukaemia. Postgraduate Haematology. 5th 
edition. UK:Blackwell Publishing Ltd; 476-490.
Bernstein, J., Dastugue, N., Haas, O.A., Harbott, J., 
Heerema, N.A., Huret, J.L., Landman-Parker, J., 
LeBeau, M.M., Leonard, C., Mann, G., Pages, 
M.P., Perot, C., Pirc-Danoewinata, H., Roitzheim, 
B., Rubin, C.M., Slociak, M. & Viguie, F. 2000. 
Nineteen cases of the t(1;22)(p13;q13) acute 
megakaryoblastic leukaemia of infants/children 
and a review of 39 cases: report from a t(1;22) 
study group. Leukaemia 14(1): 216-218. 
Carroll, A., Civin, C., Schneider, N., Dahl, G., Pappo, 
A., Bowman, P., Emami, A., Gross, S., Alvarado, 
C. & Phillips, C. 1991. The t(1;22)(p13;q13) is 
Nonrandom and Restricted to  infants with 
Acute Megakaryoblastic Leukaemia: A Pediatric 
Oncology Group Study. Blood 78(3): 748-752. 
Edmond, S.K. 2001. Case report: Acute 
megakaryoblastic leukaemia with complex 
variant 1;22 translocation. Hong Kong 
Association of Blood Transfusion and 
Haematology. 
Gewirtz, A.M. 1989. Acute megakaryocytic 
leukaemia. Mayo Clin Proc 64(11): 1447-1451. 
Lion T, Haas OA, Harbott J, Bannier E, Ritterbach J, 
Jankovic M, Fink FM, Stojimirovic A, Herrmann 
J, Riehm HJ, et al. 1992. The translocation t(1;22)
(p13;q13) is anonrandom marker specifically 
associated with acute megakaryocytic leukemia 
in young children. Blood 79(12): 3325-3330.
Ma, Z., Morris, S.W., Valentine, V., Li, M., Herbrick, 
J.A., Cui, X., Bouman, D., Li, Y., Mehta, P.K., 
Nizetic, D., Kaneko, Y., Chan, G.C., Chan, L.C., 
Squire, J., Scherer, S.W. & Hitzler, J.K. 2001. 
Fusion of two novel genes, RBM15 and MKL1, 
in the t(1;22)(p13;q13) of acute megakaryoblastic 
leukemia. Nat Genet 28(3): 220-221.
Mercher, T., Raffel, G.D., Moore, S.A., Cornejo, 
M.G., Baudry-Bluteau, D., Cagnard, N., 
Jesneck, J.L., Pikman, Y., Cullen, D., Williams, 
I.R., Akashi, K., Shigematsu, H., Bourquin, 
J.P., Giovannini, M., Vainchenker, W., Levine, 
R.L., Lee, B.H., Bernard, O.A. & Gilliland, 
D.G. 2009 The OTT-MAL fusion oncogene 
activates RBPJ-mediated transcription and 
induces acute megakaryoblastic leukaemia in a 
knockin  mouse model. The Journal of Clinical 
Investigation 119(4): 852-864.  
Ravindranath, Y., Abella, E., Krischer, J.P., Wiley, J., 
Inoue, S., Harris, M., Chauvenet, A., Alvarado, 
C.S., Dubowy, R., Ritchey, A.K., et al. 1992. 
Acute myeloid leukaemia in Down syndrom is 
highly responsive to chemotherapy: experience 
on Pediatric Oncology Group AML study 8498. 
Blood 80(9): 2210-2214.
Reinhardt, D., Diekamp, S., Langebrake, C., Ritter, 
J., Dworzak, M., Schrauder, A., Zimmermann, 
M., Fleischhack, G., Ludwig, W.D., Harbott, J. 
& Creutzig, U. 2005. Acute Megakaryoblastic 
Leukaemia in children and adolescents, 
excluding Down syndrome: improved outcome 
with intensified induction treatment. Leukaemia 
19(8): 1495-1496.
Ribeiro, R.C., Oliveira, M.S., Fairclough, D., Hurwitz, 
C., Mirro, J., Behm, F.G., Head, D., Silva, M.L., 
Raimondi, S.C. & Crist, W.M. 1993. Acute 
megakayoblastic leukaemia in children and 
adolescent : a retrospective analysis of 24 cases. 
Lymphoma 10(4-5): 299-306.
Swerdlow, S.H., Campo, E., Harris, N.L., et al. 
2008. WHO Classification of Tumours of 
Haematopoeitic and Lymphoid tissues. 4th 
edition; 17, 117, 136-137. 
Verschuur, A.C. 2004. Acute megakaryoblastic 
leukaemia. Orphanet Encyclopedia; 1-4 http://
www.orpha.net/data/patho/GB/uk-AWLM7.pdf. 
[20 December 2011] 
